290 related articles for article (PubMed ID: 18430192)
1. Use of erythropoiesis stimulating agents and intravenous iron for cancer and treatment-related anaemia: the need for predictors and indicators of effectiveness has not abated.
Katodritou E; Zervas K; Terpos E; Brugnara C
Br J Haematol; 2008 Jul; 142(1):3-10. PubMed ID: 18430192
[TBL] [Abstract][Full Text] [Related]
2. Prediction of response to optimize outcome of treatment with erythropoietin.
Beguin Y
Semin Oncol; 1998 Jun; 25(3 Suppl 7):27-34. PubMed ID: 9671327
[TBL] [Abstract][Full Text] [Related]
3. Iron supplementation and erythropoiesis-stimulatory agents in the treatment of cancer anemia.
Pedrazzoli P; Rosti G; Secondino S; Siena S
Cancer; 2009 Mar; 115(6):1169-73. PubMed ID: 19152436
[TBL] [Abstract][Full Text] [Related]
4. The use of intravenous iron in patients with cancer-related anaemia.
Littlewood TJ; Alikhan R
Br J Haematol; 2008 Jun; 141(6):751-6. PubMed ID: 18410455
[TBL] [Abstract][Full Text] [Related]
5. Potential health economic impact of intravenous iron supplementation to erythropoiesis-stimulating agent treatment in patients with cancer- or chemotherapy-induced anemia.
Szucs TD; Blank PR; Schwenkglenks M; Aapro M
Oncology; 2011; 81(1):45-9. PubMed ID: 21921645
[TBL] [Abstract][Full Text] [Related]
6. Prediction of response to treatment with recombinant human erythropoietin in anaemia associated with cancer.
Beguin Y
Med Oncol; 1998 Aug; 15 Suppl 1():S38-46. PubMed ID: 9785336
[TBL] [Abstract][Full Text] [Related]
7. Iron therapy in chronic kidney disease: current controversies.
Kovesdy CP; Kalantar-Zadeh K
J Ren Care; 2009 Dec; 35 Suppl 2():14-24. PubMed ID: 19891681
[TBL] [Abstract][Full Text] [Related]
8. Intravenous iron versus erythropoiesis-stimulating agents: friends or foes in treating chronic kidney disease anemia?
Kalantar-Zadeh K; Streja E; Miller JE; Nissenson AR
Adv Chronic Kidney Dis; 2009 Mar; 16(2):143-51. PubMed ID: 19233073
[TBL] [Abstract][Full Text] [Related]
9. Economic considerations in a changing anemia environment.
Pizzi LT
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S29-33. PubMed ID: 19010259
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review.
Qunibi WY
Arzneimittelforschung; 2010; 60(6a):399-412. PubMed ID: 20648931
[TBL] [Abstract][Full Text] [Related]
11. A comprehensive vision for intravenous iron therapy.
Coyne DW
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S14-20. PubMed ID: 19010257
[TBL] [Abstract][Full Text] [Related]
12. Economic evaluation of erythropoiesis-stimulating agents for anemia related to cancer.
Klarenbach S; Manns B; Reiman T; Reaume MN; Lee H; Lloyd A; Wiebe N; Hemmelgarn B; Tonelli M
Cancer; 2010 Jul; 116(13):3224-32. PubMed ID: 20564645
[TBL] [Abstract][Full Text] [Related]
13. Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesis-stimulating agents for anemia: a randomized, controlled trial.
Singh H; Reed J; Noble S; Cangiano JL; Van Wyck DB;
Clin J Am Soc Nephrol; 2006 May; 1(3):475-82. PubMed ID: 17699248
[TBL] [Abstract][Full Text] [Related]
14. European guidelines for the management of chemotherapy-induced anaemia and health economic aspects of treatment.
Repetto L; Moeremans K; Annemans L;
Cancer Treat Rev; 2006; 32 Suppl 2():S5-9. PubMed ID: 16725267
[TBL] [Abstract][Full Text] [Related]
15. Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron.
Henry DH; Dahl NV; Auerbach MA
Am J Hematol; 2012 Mar; 87(3):308-10. PubMed ID: 22262486
[TBL] [Abstract][Full Text] [Related]
16. Iron supplementation during treatment with erythropoiesis-stimulating agents for cancer-related anemia.
Schiavetto I; Pedrazzoli P; Basilico V; Siena S
Chemotherapy; 2008; 54(6):417-20. PubMed ID: 18824846
[TBL] [Abstract][Full Text] [Related]
17. Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the Anaemia Cancer Treatment (ACT) study.
Ludwig H; Aapro M; Bokemeyer C; Macdonald K; Soubeyran P; Turner M; Albrecht T; Abraham I
Eur J Cancer; 2009 Jun; 45(9):1603-15. PubMed ID: 19278851
[TBL] [Abstract][Full Text] [Related]
18. Correcting iron-restricted erythropoiesis and improving anemia in patients on hemodialysis: practical tips that can make a difference.
Easom A
Nephrol Nurs J; 2009; 36(5):529-37, 553. PubMed ID: 19856814
[TBL] [Abstract][Full Text] [Related]
19. Hypochromic erythrocytes (%): a reliable marker for recognizing iron-restricted erythropoiesis and predicting response to erythropoietin in anemic patients with myeloma and lymphoma.
Katodritou E; Terpos E; Zervas K; Speletas M; Kapetanos D; Kartsios C; Verrou E; Banti A; Effraimidou S; Christakis J
Ann Hematol; 2007 May; 86(5):369-76. PubMed ID: 17375302
[TBL] [Abstract][Full Text] [Related]
20. The Role of Intravenous Iron in the Treatment of Anemia Associated with Cancer and Chemotherapy.
Rodgers GM; Gilreath JA
Acta Haematol; 2019; 142(1):13-20. PubMed ID: 30970366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]